The economic cost of IPR infringement in the pharmaceutical sector
This study focuses on the economic impact of counterfeit medicines in the European Union marketplace and its wider costs to industry, government and society as a whole.
Fake medicines cost the EU pharmaceutical sector EUR 10.2 billion each year and the loss of 37 700 jobs.
The study refers only to manufacturing and wholesale and does not include retailers (e.g. pharmacies).
The main problem to get the medicine by a lot of names, such as Kamagra, Silagra, Suhagra purchase generic levitra etc. It usually tadalafil sales visit for more info is found in prostate cancer tests. One can get this information easily by online pharmacies viagra browsing the net. It is safe to keep this medicine at temperature of viagra on sale cheapest 25 degrees C.
Main findings:
- 4.4 % of sales lost annually by the sector due to counterfeiting
- EUR 10.2 billion of revenue lost annually by the sector
- Additional EUR 7.1 billion of revenue lost annually in related sectors
- 37 700 direct jobs lost annually
- 90 900 direct and indirect jobs lost annually
- EUR 1.7 billion of government revenue lost annually (taxes and social contributions)
The study covers the following products:
- manufacture of medicaments: antisera and other blood fractions, vaccines, diverse medicaments including homeopathic preparations
- manufacture of chemical contraceptive products for external use and hormonal contraceptive medicaments
- manufacture of medical diagnostic preparations, including pregnancy tests
- manufacture of radioactive in vivo diagnostic substances
- manufacture of biotech pharmaceuticals
